^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    rilvegostomig (AZD2936)

    i
    Other names: AZD2936, AZD-2936, AZD 2936
    Company:
    AstraZeneca, Compugen, Xoma
    Drug class:
    PD1 inhibitor, TIGIT inhibitor
    Related drugs:
    19h
    LIBRA: A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov)
    P2, N=278, Recruiting, AstraZeneca | Trial primary completion date: Mar 2027 --> Apr 2029
    Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)
    |
    ALK rearrangement
    |
    Cyramza (ramucirumab) • Datroway (datopotamab deruxtecan-dlnk) • rilvegostomig (AZD2936)
    10d
    TROPION-Lung12: A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma NSCLC Who Are ctDNA-positive or Have High-risk Pathological Features (clinicaltrials.gov)
    P3, N=24, Active, not recruiting, AstraZeneca | N=660 --> 24 | Trial completion date: Jan 2035 --> Jun 2027 | Trial primary completion date: May 2033 --> Jun 2027 | Recruiting --> Active, not recruiting
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date • Circulating tumor DNA
    |
    cisplatin • carboplatin • pemetrexed • etoposide IV • vinorelbine tartrate • Datroway (datopotamab deruxtecan-dlnk) • rilvegostomig (AZD2936)
    28d
    AB02: A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02) (clinicaltrials.gov)
    P3, N=1100, Recruiting, AstraZeneca | Not yet recruiting --> Recruiting
    Enrollment open
    |
    PD-L1 (Programmed death ligand 1)
    |
    cisplatin • Imfinzi (durvalumab) • gemcitabine • rilvegostomig (AZD2936)
    1m
    ARTEMIDE-subQ: A Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Rilvegostomig in Adult Participants With Advanced Solid Tumors Previously Treated With Standard of Care Therapy (clinicaltrials.gov)
    P1, N=40, Recruiting, AstraZeneca | Not yet recruiting --> Recruiting | Trial completion date: Mar 2028 --> Jul 2029 | Trial primary completion date: Aug 2026 --> Jul 2027
    Enrollment open • Trial completion date • Trial primary completion date
    |
    rilvegostomig (AZD2936)
    2ms
    ALTAIR: A Platform Study in Non-Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov)
    P1/2, N=152, Recruiting, AstraZeneca | Not yet recruiting --> Recruiting | Trial completion date: Oct 2028 --> Feb 2029 | Trial primary completion date: Oct 2028 --> Feb 2029
    Enrollment open • Trial completion date • Trial primary completion date
    |
    cisplatin • carboplatin • albumin-bound paclitaxel • Cyramza (ramucirumab) • pemetrexed • rilvegostomig (AZD2936)
    3ms
    GEMINI-Hepatobiliary: Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer (clinicaltrials.gov)
    P2, N=294, Recruiting, AstraZeneca | Trial completion date: Dec 2026 --> Oct 2027 | Trial primary completion date: Dec 2025 --> Oct 2026
    Trial completion date • Trial primary completion date
    |
    Avastin (bevacizumab) • cisplatin • gemcitabine • Lenvima (lenvatinib) • rilvegostomig (AZD2936) • volrustomig (MEDI5752)
    3ms
    AB02: A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02) (clinicaltrials.gov)
    P3, N=1100, Not yet recruiting, AstraZeneca
    New P3 trial
    |
    PD-L1 (Programmed death ligand 1)
    |
    cisplatin • Imfinzi (durvalumab) • gemcitabine • rilvegostomig (AZD2936)
    4ms
    Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03) (clinicaltrials.gov)
    P2, N=413, Recruiting, AstraZeneca | Trial completion date: Jul 2026 --> Jun 2027 | Trial primary completion date: Jul 2026 --> Jun 2027
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive
    |
    Keytruda (pembrolizumab) • cisplatin • Imfinzi (durvalumab) • 5-fluorouracil • Enhertu (fam-trastuzumab deruxtecan-nxki) • capecitabine • oxaliplatin • rilvegostomig (AZD2936) • volrustomig (MEDI5752)
    4ms
    A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1/2, N=60, Recruiting, AstraZeneca | Trial completion date: Apr 2029 --> Oct 2029 | Trial primary completion date: Apr 2029 --> Oct 2029
    Trial completion date • Trial primary completion date
    |
    rilvegostomig (AZD2936)
    4ms
    BLUESTAR: A Phase I/IIa Study of AZD8205 Given Alone or in Combination With Anticancer Drugs, in Participants With Advanced or Metastatic Solid Malignancies (clinicaltrials.gov)
    P1/2, N=370, Recruiting, AstraZeneca | Trial completion date: Mar 2027 --> Sep 2027 | Trial primary completion date: Mar 2027 --> Sep 2027
    Trial completion date • Trial primary completion date
    |
    puxitatug samrotecan (AZD8205) • saruparib (AZD5305) • rilvegostomig (AZD2936)
    4ms
    LIBRA: A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov)
    P2, N=278, Recruiting, AstraZeneca | Not yet recruiting --> Recruiting | Trial primary completion date: Sep 2026 --> Mar 2027
    Enrollment open • Trial primary completion date
    |
    Cyramza (ramucirumab) • Datroway (datopotamab deruxtecan-dlnk) • rilvegostomig (AZD2936)
    5ms
    TROPION-Lung12: A phase 3 study of adjuvant datopotamab deruxtecan and rilvegostomig in ctDNA-positive or high-risk pathology stage I NSCLC. (PubMed, J Thorac Cardiovasc Surg)
    Patients will be randomized 2:1:2 to receive Dato-DXd (6 mg/kg IV Q3W) plus rilvegostomig (750 mg IV Q3W) for 4 cycles followed by rilvegostomig (up to 12 months/18 cycles total); rilvegostomig alone (up to 12 months/18 cycles total); or standard of care (SoC) for up to 12 months. The primary endpoint is disease-free survival assessed using blinded independent central review per RECIST v1.1, with key secondary endpoints including overall survival, for Dato-DXd plus rilvegostomig vs SoC arms.
    P3 data • Journal • PD(L)-1 Biomarker • IO biomarker • Circulating tumor DNA
    |
    TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2)
    |
    Datroway (datopotamab deruxtecan-dlnk) • rilvegostomig (AZD2936)